Despite most of the world putting their attention towards COVID-19, cardiovascular disease is still the world-leading healthcare crisis. Esperion Therapeutics (ESPR) is attempting to alleviate that enduring problem with its affordable, convenient, oral, once-daily, non-statin, LDL-C medicines. The company recently received FDA approval for both NEXLETOL and NEXLIZET in late February as well as EU approvals for both NILEMDO and NUSTENDI last month. What is more, the company recently closed a partnership deal in Japan with Otsuka Pharmaceutical, which was the biggest-ever Japan development and commercial collaboration agreement in history. In addition, the